Anthropic to develop its own drugs
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Anthropic announced Claude Science, an "AI workbench for scientists" that pulls fragmented tools and datasets into one environment and generates figures and visuals, at "The Briefing: AI for Science" earlier this week.
- Anthropic said it will develop its own drugs, with head of life sciences Eric Kauderer-Abrams saying the company will focus on discovering treatments for "neglected" diseases.
- Anthropic's move makes it one of the most direct public attempts by a frontier AI company to develop drugs itself, putting it in the unusual position of selling software to potentially competing drugmakers — joining a field that includes Insilico, Google DeepMind spinout Isomorphic Labs, and Big Pharma.
- Anthropic has been actively hiring biologists, building its own wet labs, and recruiting from Big Pharma and prestigious academic institutions, according to University of Cambridge professor Namshik Han.
- Experts including Han and UCL professor Matthew Todd said AI is applied at "every single stage of drug discovery" but stressed no AI-designed drug has yet received FDA approval, with clinical timelines likely putting any payoff "at the very least, the better part of a decade" away.
- Frank von Delft of Oxford warned that AI models "haven't yet come close to making experiments unnecessary," meaning Anthropic "is going to have to spend a lot on experiments" if it pursues drug development.
- Anthropic did not specify which diseases it will target first, whether it will partner for lab work, animal testing, clinical trials, or manufacturing, or what it would do with promising drug candidates.
Why it matters: Anthropic is blurring the line between AI vendor and drug developer — selling Claude to pharma while simultaneously racing them, a conflict OpenAI, Google, and Amazon have so far avoided. With no FDA-approved AI-designed drugs to date and clinical timelines measured in decades, the company is committing to spend heavily on wet-lab experiments and biology hires before any candidate could plausibly reach patients.
